Feng X, Chai YH, Jiang KX, Jiang WB, Chen WC, Pan Y. Bibliometric analysis of olaparib and pancreatic cancer from 2009 to 2022: A global perspective. World J Gastrointest Oncol 2024; 16(11): 4489-4505 [PMID: 39554747 DOI: 10.4251/wjgo.v16.i11.4489]
Corresponding Author of This Article
Yu Pan, MD, Physiotherapist, Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Qingchun East Road, Shangcheng District, Hangzhou 310016, Zhejiang Province, China. panyu1013@zju.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Scientometrics
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Xu Feng, Yi-Han Chai, Ke-Xin Jiang, Wen-Bin Jiang, Wen-Chao Chen, Yu Pan, Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang Province, China
Co-first authors: Xu Feng and Yi-Han Chai.
Co-corresponding authors: Wen-Chao Chen and Yu Pan.
Author contributions: Feng X and Jiang KX were responsible for conceptualization; Chai YH and Pan Y were responsible for methodology; Jiang KX and Feng X were responsible for investigation; Pan Y, Feng X and Chai YH were responsible for visualization; Chen WC, Jiang WB and Feng X were responsible for supervision; Feng X and Chen WC were responsible for writing – original draft; Pan Y, Feng X and Jiang WB were responsible for writing – review & editing. Feng X and Chai YH are listed as co-first authors for their contributions to both the research and the manuscript. They share responsibility as well as accountability for the work delivered and the research that has been conducted, including substantial contributions to the conception or design of the work, drafting the work or revising it critically for important intellectual content, final approval of the version to be published, and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Chen WC and Pan Y are listed as co-corresponding authors for their contributions to this manuscript. They have read and agreed to the published version of the manuscript, ensuring that all aspects of the work are accurately represented and that all conditions for authorship are met.
Supported bythe Zhejiang Provincial Medical and Health Science and Technology Program, No. 2024KY1109.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yu Pan, MD, Physiotherapist, Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Qingchun East Road, Shangcheng District, Hangzhou 310016, Zhejiang Province, China. panyu1013@zju.edu.cn
Received: June 4, 2024 Revised: August 24, 2024 Accepted: September 27, 2024 Published online: November 15, 2024 Processing time: 142 Days and 19.9 Hours
Abstract
BACKGROUND
Genetic screening for breast cancer gene 1 (BRCA)1/2 mutations can inform breast/ovarian/pancreatic cancer patients of suitable therapeutic interventions. Four to seven percent of pancreatic cancer patients have germline BRCA mutations. BRCA genes aid in DNA repair, especially homologous recombination, which impacts genomic stability and cancer cell growth. BRCA1 regulates the cell cycle, ubiquitination, and chromatin remodeling, whereas BRCA2 stimulates the immune response. They predict the efficacy of platinum chemotherapy or polymerase (PARP) inhibitors such as olaparib.
AIM
To determine the trends and future directions in the use of olaparib for pancreatic cancer treatment.
METHODS
To evaluate the trends in how olaparib works in pancreatic cancer, we performed a bibliometric analysis. One hundred and ninety-six related publications were accessed from the Web of Science Core Collection and were published between 2009 and 2022. The analytic parameters included publications, related citations, productive countries and institutes, influential authors, and keyword development.
RESULTS
This study visualizes and discusses the current research, including the present global trends and future directions in olaparib and pancreatic cancer. Overall, this study sheds light on optimizing the use of olaparib in pancreatic cancer treatment, offering valuable guidance for researchers in this field.
CONCLUSION
Our findings identified trends in olaparib and pancreatic cancer, with China and the USA leading and with global cooperation tightening. O'Reilly EM's team and Memorial Sloan-Kettering had the highest output. The Journal of Clinical Oncology was the most cited journal. More PARP inhibitors are emerging, and combination therapy is suggested for future therapeutic trends.
Core Tip: Breast cancer gene (BRCA)1 and BRCA2 mutations affect 4%-7% of pancreatic cancer patients and influence their response to therapies such as platinum chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib. A bibliometric analysis of 196 publications highlights growing global research interest, with China and the United States leading. The key contributors include O'Reilly EM's team and Memorial Sloan-Kettering, whereas the Journal of Clinical Oncology stands out for citations. Future trends point toward increased use of PARP inhibitors and combination therapies, offering valuable insights for advancing olaparib research in pancreatic cancer.
